United Therapeutics CorporationUnited Therapeutics CorporationUnited Therapeutics Corporation

United Therapeutics Corporation

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪14.58 B‬USD
‪984.80 M‬USD
‪2.33 B‬USD
‪43.59 M‬
Beta (1Y)

About United Therapeutics Corporation

Martine A. Rothblatt
Silver Spring
Employees (FY)
‪1.17 K‬
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where UTHR is featured.

Frequently Asked Questions

The current price of UTHR is 329.44 USD — it has increased by 0.23% in the past 24 hours. Watch United Therapeutics Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange United Therapeutics Corporation stocks are traded under the ticker UTHR.
UTHR stock has risen by 1.09% compared to the previous week, the month change is a 10.54% rise, over the last year United Therapeutics Corporation has showed a 35.09% increase.
We've gathered analysts' opinions on United Therapeutics Corporation future price: according to them, UTHR price has a max estimate of 400.00 USD and a min estimate of 240.00 USD. Watch UTHR chart and read a more detailed United Therapeutics Corporation stock forecast: see what analysts think of United Therapeutics Corporation and suggest that you do with its stocks.
UTHR reached its all-time high on Jul 12, 2024 with the price of 330.00 USD, and its all-time low was 4.28 USD and was reached on Dec 11, 2001. View more price dynamics on UTHR chart.
See other stocks reaching their highest and lowest prices.
UTHR stock is 1.60% volatile and has beta coefficient of 0.30. Track United Therapeutics Corporation stock price on the chart and check out the list of the most volatile stocks — is United Therapeutics Corporation there?
Today United Therapeutics Corporation has the market capitalization of ‪14.58 B‬, it has increased by 4.67% over the last week.
Yes, you can track United Therapeutics Corporation financials in yearly and quarterly reports right on TradingView.
United Therapeutics Corporation is going to release the next earnings report on Jul 31, 2024. Keep track of upcoming events with our Earnings Calendar.
UTHR earnings for the last quarter are 6.17 USD per share, whereas the estimation was 5.71 USD resulting in a 8.13% surprise. The estimated earnings for the next quarter are 6.42 USD per share. See more details about United Therapeutics Corporation earnings.
United Therapeutics Corporation revenue for the last quarter amounts to ‪677.70 M‬ USD, despite the estimated figure of ‪620.31 M‬ USD. In the next quarter, revenue is expected to reach ‪690.14 M‬ USD.
UTHR net income for the last quarter is ‪306.60 M‬ USD, while the quarter before that showed ‪217.10 M‬ USD of net income which accounts for 41.23% change. Track more United Therapeutics Corporation financial stats to get the full picture.
No, UTHR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 19, 2024, the company has ‪1.17 K‬ employees. See our rating of the largest employees — is United Therapeutics Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. United Therapeutics Corporation EBITDA is ‪1.31 B‬ USD, and current EBITDA margin is 53.35%. See more stats in United Therapeutics Corporation financial statements.
Like other stocks, UTHR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade United Therapeutics Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So United Therapeutics Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating United Therapeutics Corporation stock shows the strong buy signal. See more of United Therapeutics Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.